Encysive launches Thelin in USA
The USA's Encysive Pharmaceuticals has launched Thelin (sitaxentan sodium) 100mg tablets in France for the treatment of pulmonary arterial hypertension. The firm received European Union marketing authorization for the agent from the European Commission in August 2006 and it is the first selective endothelin A receptor antagonist, and the first once-daily oral treatment available for patients with PAH.
Thelin is indicated for improving exercise capacity in PAH patients classified as World Health Organization functional class III. According to the firm, the drug's efficacy has been shown in both primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.
The European Commission's centralized licensing procedure permits Encysive to market Thelin in all 27 member states of the EU. The agent has already been launched in the UK, Germany, Ireland, Spain and the Netherlands and will be introduced in additional EU member states as local governmental reimbursement approval is obtained.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze